Age, y, mean ± SD | 66 ± 9 | 64 ± 10 | 67 ± 8 | 0.212 |
Men | 48 (62) | 14 (40) | 34 (81) | 0.003 |
Body mass index, kg/m2, mean ± SD | 27 ± 4 | 26 ± 4 | 27 ± 4 | 0.338 |
Arterial hypertension | 56 (73) | 24 (69) | 32 (76) | 0.623 |
Diabetes mellitus | 14 (18) | 3 (9) | 11 (26) | 0.046 |
Current smoker | 27 (35) | 9 (26) | 18 (43) | 0.173 |
Former smoker | 9 (12) | 2 (6) | 7 (17) | 0.101 |
Typical angina | 26 (34) | 7 (20) | 19 (45) | 0.020 |
Atypical angina | 18 (23) | 13 (37) | 5 (12) | 0.009 |
Asymptomatic | 16 (21) | 5 (14) | 11 (26) | 0.200 |
Total cholesterol (mmol/L), mean ± SD | 5.0 ± 1.1 | 4.9 ± 1.1 | 5.0 ± 1.0 | 0.516 |
Low-density lipoprotein cholesterol (mmol/L), mean ± SD | 2.8 ± 1.1 | 2.7 ± 1.0 | 2.9 ± 1.1 | 0.694 |
High-density lipoprotein cholesterol (mmol/L), mean ± SD | 1.4 ± 0.4 | 1.5 ± 0.4 | 1.3 ± 0.4 | 0.153 |
Triglyceride (mmol/L), mean ± SD | 1.6 ± 0.9 | 1.7 ± 1.0 | 1.6 ± 0.8 | 0.931 |
Framingham Heart Study risk score, mean ± SD† | 13 ± 5 | 10 ± 5 | 15 ± 5 | 0.005 |
Current medication | | | | |
Antiplatelet drug | 22 (29) | 7 (20) | 15 (36) | 0.234 |
Statin | 29 (38) | 11 (31) | 18 (43) | 0.491 |
β-Blocker | 33 (43) | 12 (34) | 21 (50) | 0.373 |
Angiotensin-converting enzyme inhibitor or angiotensin II receptor antagonist | 33 (43) | 12 (34) | 21 (50) | 0.373 |
Ca2+ antagonist | 9 (12) | 4 (11) | 5 (12) | 0.963 |